NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球人類基因測序診斷市場:策略/趨勢、未來預測(使用/技術/工作流程/產品/國家)、對執行顧問的建議(2021-2025)

Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Application, by Technology, by Workflow, by Product, and by Country. With Executive and Consultant Guides. 2021 to 2025

出版商 Howe Sound Research 商品編碼 1005155
出版日期 內容資訊 英文 718 Pages
商品交期: 最快1-2個工作天內
價格
全球人類基因測序診斷市場:策略/趨勢、未來預測(使用/技術/工作流程/產品/國家)、對執行顧問的建議(2021-2025) Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Application, by Technology, by Workflow, by Product, and by Country. With Executive and Consultant Guides. 2021 to 2025
出版日期: 2021年05月10日內容資訊: 英文 718 Pages
簡介

全球基因測序市場因成本降低而陷入淘金熱,新消費者、新技術和新利基市場不斷湧現,讓人想起互聯網行業的早期。各種資金雄厚的公司正在爭奪市場份額。

本報告分析了人類基因測序未來的技術進步和市場增長前景,並概述了迄今為止的技術、主要應用領域、主要市場推動/制約因素、技術傳播/滲透。主要公司和主要產品,未來市場規模趨勢預測(至 2025 年),按地區(5 個地區,共 14 個國家)和按應用、技術、工作流程、產品我們將向您發送詳細趨勢等信息。

目錄

第 1 章市場指南

  • 人類基因測序市場:戰略情境邏輯和新型冠狀病毒感染 (COVID-19)
  • 影響
  • 給執行營銷、銷售和業務開發人員的建議
  • 給管理顧問和投資顧問的建議

第 2 章介紹,市場定義

  • 本報告中基因測序的定義
  • 基因組學革命
  • 市場定義
    • 市場規模/利潤金額
  • 美國醫療市場和實驗室檢測:前景
    • 在美國用於臨床測試的醫療保險支出
  • 基因檢測和基因測序
    • 成本和定價實踐

第 3 章測序設備安裝基地:世界位置和聯繫方式列表

第 4 章市場概覽

  • 市場參與者扮演的各種角色
    • 測量設備製造商
    • 獨立實驗室:專業
    • 獨立實驗室:國家/地區
    • 獨立實驗室:分析
    • 國家/公共實驗室
    • 醫院實驗室
    • 從業者實驗室
    • DTC 實驗室
    • 測序實驗室
    • 審計機構
  • 人類基因測序:市場、案例研究、討論
    • 遺傳性疾病:與以往不同
    • 新生兒篩查:標準治療
    • NIPT:才剛剛開始
    • 腫瘤學:瞭解兩個世界
    • 藥理學基因組學
    • DTC(直接面向消費者):不僅僅是眼前所見
  • 產業結構
    • 醫院檢查佔比
    • 測序實驗室的興起
    • 測序作為產品
    • 信息學
    • 設備製造商的角色
    • 對醫療行業的影響:仍在苦苦掙扎
    • 醫療行業適應潛力
    • 遺傳諮詢作為一個行業
    • 序列化和同類化(同類化現象)介紹

第 5 章市場趨勢

  • 推動市場增長的因素
    • 新的診斷方法
    • 健康/疾病預防
    • 不孕不育治療技術
    • 癌症:篩查/管理/監測
  • 抑制市場增長的因素
    • 競爭加劇導致價格下降
    • 低成本
    • 擔心醫療費用上漲導致增長受限
    • 健康的缺點
  • 測序儀器儀表
    • 儀器工作的不懈努力
    • 設備成本降低導致行業結構變化
    • 當前設備規格列表
    • 長期領先:進一步劃分
    • 帶有鏈接的線索
    • 新的測序技術

第 6 章人類基因測序:最新進展

  • 近期趨勢:本節的重要性以及如何使用它
    • 近期趨勢的重要性
    • 如何使用本報告

第 7 章主要公司概況

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • Aperiomics
  • Arc Bio
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Cepheid(now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health(Beijing)Co., Ltd.
  • Genewiz
  • Genomics England
  • Genomics Personalized Health(GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Lexagene
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron Pharmaceuticals
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • SeLux Diagnostics
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

第 8 章全球人類基因組測序市場

  • 國家/地區分析:概述
  • 應用分析:概述
  • 技術分析:概述
  • 按工作流程分析:概述
  • 產品分析:概述

第 9 章按應用劃分的市場規模

  • 遺傳基因測序市場
  • NIPT基因測序市場
  • 腫瘤市場
  • 心理市場
  • WGES 基因測序市場
  • 藥理學基因組學市場
  • DTC基因測序市場
  • 研究基因測序市場
  • 其他市場

第 10 章按技術劃分的市場規模

  • 桑格測序市場
  • NGS/2G 市場
  • 3G/多頭市場
  • 其他市場

第 11 章按工作流程劃分的市場規模

  • 測序市場
  • 樣品製備市場
  • 分析市場

第 12 章按產品劃分的市場規模

  • 分析儀市場
  • 耗材市場
  • 軟件服務市場

第 13 章人類基因測序的未來展望

第 14 章附錄

目錄

OVERVIEW:

Will all newborns receive genetic testing at birth? What segments are growing fastest? Where are the over 800 locations that have high throughput sequencing devices?

Our facts and support = Your success.

The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Human Gene Sequencing Markets - Strategic Situation Analysis & COVID
  • Impact
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 Gene Sequencing Definition In This Report
    • 2.1.1 Gene Sequencing
    • 2.1.2 Hereditary
    • 2.1.3 Non Invasive Prenatal Testing
    • 2.1.4 Oncology
    • 2.1.5 Psychology
    • 2.1.6 WGES
    • 2.1.7 Pharmacogenomic
    • 2.1.8 Direct to Consumer
    • 2.1.9 Research
    • 2.1.10 Other
  • 2.2 The Genomics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 U.S. Medical Market and laboratory Testing - Perspective
    • 2.4.1 U.S. Medicare Expenditures for laboratory testing
  • 2.5 Genetic Testing vs. Gene Sequencing
    • 2.5.1 Cost and Pricing Practice

3 Global Listing of Sequencer Installed Base - Location & Contacts

  • 3.1 Notes to Installed Base Listing
  • 3.2 Illumina Installed Base

4 Market Overview

  • 4.1 Market Participants Play Different Roles
    • 4.1.1 Instrument Manufacturer
    • 4.1.2 Independent lab specialized/esoteric
    • 4.1.3 Independent lab national/regional
    • 4.1.4 Independent lab analytical
    • 4.1.5 Public National/regional lab
    • 4.1.6 Hospital lab
    • 4.1.7 Physician lab
    • 4.1.8 DTC Lab
    • 4.1.9 Sequencing Labs
    • 4.1.10 Audit body
  • 4.2 Human Gene Sequencing -Markets, Examples and Discussion
    • 4.2.1 Inherited Disease - Not what it used to be
      • 4.2.1.1 Clinical and Research Lines Blur
      • 4.2.1.2 Genetic Counselling - Not so simple anymore
      • 4.2.1.3 The Genetic Blizzard - Issues of Access and Payment
    • 4.2.2 Newborn Screening - The Standard of Care
      • 4.2.2.1 Newborn Screening - Do Parents Want to Know?
    • 4.2.3 NIPT - We've Only Just Begun
      • 4.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS
      • 4.2.3.2 NIPT in the Future - Beyond Inherited Disease
    • 4.2.4 Oncology - Understanding Two Worlds
      • 4.2.4.1 The Tumor - A Sequence of Sequencing
      • 4.2.4.2 The Tumor - Biopsy and Liquid Biopsy
      • 4.2.4.3 The Human Genome - Predisposition and Prognosis
    • 4.2.5 Pharmacogenomics
      • 4.2.5.1 Sequencing Not the Only Player
      • 4.2.5.2 New Roles for Old Drugs - A Research Bonanza?
    • 4.2.6 Direct To Consumer - More Than Meets the Eye
      • 4.2.6.1 DTC - How Many Segments?
  • 4.3 Industry Structure
    • 4.3.1 Hospital's Testing Share
    • 4.3.2 The Rise of the Sequencing Lab
    • 4.3.3 Sequencing as a Commodity
    • 4.3.4 Informatics
    • 4.3.5 Instrument Manufacturer Role
    • 4.3.6 Healthcare Industry Impacts - Still Struggling
    • 4.3.7 Can the Healthcare Industry Adapt?
    • 4.3.8 Genetic Counselling as an Industry
    • 4.3.9 Sequencing Adoption and Cannibalization

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 New Diagnoses
    • 5.1.2 Wellness and Prevention
    • 5.1.3 Fertility Technology
    • 5.1.4 Cancer - Screening, Management and Monitoring
  • 5.2 Factors Limiting Growth
    • 5.2.1 Increased Competition Lowers Price
    • 5.2.2 Lower Costs
    • 5.2.3 Healthcare Cost Concerns Curtail Growth
    • 5.2.4 Wellness has a downside
  • 5.3 Sequencing Instrumentation
    • 3.3.1 Instrumentation Tenacity.
    • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
    • 3.3.3 Listing of Current Instrument Specifications
    • 5.3.1 Long Reads - Further Segmentation
    • 5.3.2 Linked Reads
    • 5.3.3 New Sequencing Technologies

6 Human Gene Sequencing Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Myriad Genetics Projects Return to Profitability
  • 6.3 NeoGenomics to Acquire Inivata
  • 6.4 OncoDNA, Institut Curie Partner on Liquid Biopsy Research
  • 6.5 Cancer Heritability Gene Set Expanded
  • 6.6 Whole-Genome Sequencing Could Replace Cytogenetics
  • 6.7 Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays
  • 6.8 Ancestry Shutters Health Offering
  • 6.9 Genetron Health Targeting Early Cancer Detection
  • 6.10 Pan-European Initiative to Build Tools for Sharing Genomic Data
  • 6.11 UK Government Unveils New Genomic Healthcare Strategy
  • 6.12 Foundation Medicine Liquid Biopsy Gets FDA Approval
  • 6.13 American Heart Association Develops Genetic Testing Guidelines
  • 6.14 Yourgene Health Gets CE Mark for Iona NIPT Test
  • 6.15 NorthShore Looks to Expand Genomics Integration Into Primary Care
  • 6.16 Germline Results From Tumor Sequencing Guides Precision Therapy
  • 6.17 FDA Clears Cancer Genomic Profiling From Personal Genome Diagnostics
  • 6.18 BillionToOne Closes $15M Series A Follow-on Round
  • 6.19 Clinics to Integrate Genomics Into Primary Care
  • 6.20 Asuragen Fragile X Diagnostic Test Gets FDA Authorization
  • 6.21 Fluxion Bio Wins NIH Grant to Develop NIPT Assay
  • 6.22 Illumina, Broad Institute Collaborate on Software
  • 6.23 Illumina, Adaptive Biotechnologies Partner
  • 6.24 Menarini Silicon Biosystems, BlueBee Partner
  • 6.25 Paying cash for elective genomic sequencing
  • 6.26 NIH funds Color ahead of million-person sequencing
  • 6.27 Veritas Genetics slashes price of WGS to $600
  • 6.28 Superfast gene sequencing diagnoses critically ill patients
  • 6.29 Veracyte Details Clinical Utility of RNA Sequencing
  • 6.30 Longas Technologies Launches
  • 6.31 Blood Test Detects Colorectal Cancer Recurrence Earlier
  • 6.32 PerkinElmer Genomics Introduces Genetic Screening Test
  • 6.33 Roche Gets CE Mark for Mutation Profiler Software
  • 6.34 PGDx and PathGroup Enter Co-Development Agreement
  • 6.35 Newborn genomic sequencing detects unanticipated disease risk factors

7 Profiles of Key Companies

  • 7.1 10x Genomics, Inc
  • 7.2 23andME Inc
  • 7.3 Abbott Diagnostics
  • 7.4 AccuraGen Inc
  • 7.5 Adaptive Biotechnologies
  • 7.6 Admera Health, LLC
  • 7.7 Agena Bioscience, Inc
  • 7.8 Agilent
  • 7.9 Akonni Biosystems
  • 7.10 Ancestry.com LLC
  • 7.11 Anchor Dx
  • 7.12 Aperiomics
  • 7.13 Arc Bio
  • 7.14 ArcherDx, Inc.
  • 7.15 ARUP Laboratories
  • 7.16 Asuragen
  • 7.17 Baylor Miraca Genetics Laboratories
  • 7.18 Beckman Coulter Diagnostics
  • 7.19 Becton, Dickinson and Company
  • 7.20 BGI Genomics Co. Ltd
  • 7.21 Bioarray Genetics
  • 7.22 Biocept, Inc
  • 7.23 Biodesix Inc.
  • 7.24 BioFluidica
  • 7.25 BioGenex
  • 7.26 Biolidics Ltd
  • 7.27 bioMérieux Diagnostics
  • 7.28 Bioneer Corporation
  • 7.29 Bio-Rad Laboratories, Inc.
  • 7.30 Bio-Techne
  • 7.31 C2i Genomics
  • 7.32 Cancer Genetics
  • 7.33 Caris Molecular Diagnostics
  • 7.34 CellMax Life
  • 7.35 Centogene
  • 7.36 Cepheid (now Danaher)
  • 7.37 Chronix Biomedical
  • 7.38 Circulogene
  • 7.39 Clinical Genomics
  • 7.40 Color Genomics
  • 7.41 Complete Genomics, Inc. - A BGI Company
  • 7.42 Cynvenio
  • 7.43 Dante Labs
  • 7.44 Datar Cancer Genetics Limited
  • 7.45 Diasorin S.p.A.
  • 7.46 Epic Sciences
  • 7.47 Epigenomics AG
  • 7.48 Eurofins Scientific
  • 7.49 Excellerate Bioscience
  • 7.50 Exosome Diagnostics
  • 7.51 Fabric Genomics
  • 7.52 Fluidigm Corp
  • 7.53 Foundation Medicine
  • 7.54 Freenome
  • 7.55 FUJIFILM Wako Diagnostics
  • 7.56 Fujirebio
  • 7.57 Fulgent Genetics
  • 7.58 GE Global Research
  • 7.59 Gene by Gene, Ltd.
  • 7.60 Genedrive
  • 7.61 GeneFirst Ltd.
  • 7.62 Genetron Health (Beijing) Co., Ltd.
  • 7.63 Genewiz
  • 7.64 Genomics England
  • 7.65 Genomics Personalized Health (GPH)
  • 7.66 GenomOncology
  • 7.67 Genzyme Corporation
  • 7.68 Grail, Inc.
  • 7.69 Grifols
  • 7.70 Guardant Health
  • 7.71 Guardiome
  • 7.72 HeiScreen
  • 7.73 Helix
  • 7.74 Helomics
  • 7.75 Hologic
  • 7.76 Horizon Discovery
  • 7.77 HTG Molecular Diagnostics
  • 7.78 Human Longevity, Inc
  • 7.79 iCellate
  • 7.80 Illumina
  • 7.81 Incell Dx
  • 7.82 Inivata
  • 7.83 Integrated Diagnostics
  • 7.84 Invitae Corporation
  • 7.85 Invivoscribe
  • 7.86 Karius
  • 7.87 Lexagene
  • 7.88 Macrogen
  • 7.89 MDNA Life SCIENCES, Inc.
  • 7.90 MDx Health
  • 7.91 Medgenome
  • 7.92 Meridian Bioscience
  • 7.93 Mesa Biotech
  • 7.94 MIODx
  • 7.95 miR Scientific
  • 7.96 MNG Labs
  • 7.97 Molecular MD
  • 7.98 NantHealth, Inc.
  • 7.99 Natera
  • 7.100 Nebula Genomics
  • 7.101 NeoGenomics
  • 7.102 Novogene Bioinformatics Technology Co., Ltd
  • 7.103 Omega Bioservices
  • 7.104 OncoDNA
  • 7.105 OpGen
  • 7.106 ORIG3N, Inc
  • 7.107 Origene Technologies
  • 7.108 Oxford Nanopore Technologies
  • 7.109 Panagene
  • 7.110 Perkin Elmer
  • 7.111 Personal Genome Diagnostics
  • 7.112 Personalis
  • 7.113 Precipio
  • 7.114 PrecisionMed
  • 7.115 Promega
  • 7.116 Protagen Diagnostics
  • 7.117 Qiagen Gmbh
  • 7.118 Quantumdx
  • 7.119 Regeneron Pharmaceuticals
  • 7.120 Roche Molecular Diagnostics
  • 7.121 Roswell Biotechnologies
  • 7.122 Seegene
  • 7.123 SeLux Diagnostics
  • 7.124 Sequencing.com
  • 7.125 Siemens Healthineers
  • 7.126 simfo GmbH
  • 7.127 Singlera Genomics Inc.
  • 7.128 SkylineDx
  • 7.129 Stratos Genomics
  • 7.130 Sure Genomics, Inc.
  • 7.131 Sysmex
  • 7.132 Sysmex Inostics
  • 7.133 Tempus Labs, Inc.
  • 7.134 Thermo Fisher Scientific Inc.
  • 7.135 Veritas Genetics
  • 7.136 Volition

8 The Global Market for Human Genome Sequencing

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Application - Overview
    • 8.2.1 Table - Global Market by Application
    • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Application - Base Year
    • 8.2.4 Chart - Global Market by Application - Final Year
    • 8.2.5 Chart - Global Market by Application - Share by Year
    • 8.2.6 Chart - Global Market by Application - Segment Growth
  • 8.3 Global Market by Technology - Overview
    • 8.3.1 Table - Global Market by Technology
    • 8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Technology - Base Year
    • 8.3.4 Chart - Global Market by Technology - Final Year
    • 8.3.5 Chart - Global Market by Technology - Share by Year
    • 8.3.6 Chart - Global Market by Technology - Segment Growth
  • 8.4 Global Market by Workflow - Overview
    • 8.4.1 Table - Global Market by Workflow
    • 8.4.2 Chart - Global Market by Workflow - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Workflow - Base Year
    • 8.4.4 Chart - Global Market by Workflow - Final Year
    • 8.4.5 Chart - Global Market by Workflow - Share by Year
    • 8.4.6 Chart - Global Market by Workflow - Segment Growth
  • 8.5 Global Market by Product - Overview
    • 8.5.1 Table - Global Market by Product
    • 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.5.3 Chart - Global Market by Product - Base Year
    • 8.5.4 Chart - Global Market by Product - Final Year
    • 8.5.5 Chart - Global Market by Product - Share by Year
    • 8.5.6 Chart - Global Market by Product - Segment Growth

9 Market Sizes by Application

  • 9.1 Hereditary Gene Sequencing Market
    • 9.1.1 Table - Hereditary by Country
    • 9.1.2 Chart - Hereditary Segment Growth
  • 9.2 NIPT Gene Sequencing Market
    • 9.2.1 Table NIPT by Country
    • 9.2.2 Chart - NIPT Growth
  • 9.3 Oncology Market
    • 9.3.1 Table - Oncology by Country
    • 9.3.2 Chart - Oncology Growth
  • 9.4 Psychology Market
    • 9.4.1 Table - Psychology by Country
    • 9.4.2 Chart - Psychology Growth
  • 9.5 WGES Gene Sequencing Market
    • 9.5.1 Table - WGES by Country
    • 9.5.2 Chart - WGES growth
  • 9.6 Pharmacogenomics Market
    • 9.6.1 Table Pharmacogenomics by Country
    • 9.6.2 Chart - Pharmacogenomics Growth
  • 9.7 DTC Gene Sequencing Market
    • 9.7.1 Table - DTC by Country
    • 9.7.2 Chart - DTC Growth
  • 9.8 Research Gene Sequencing Market
    • 9.8.1 Table - Research by Country
    • 9.8.2 Chart - Research Growth
  • 9.9 Other Application Market
    • 9.9.1 Table - Other Application by Country
    • 9.9.2 Chart - Other Application growth

10 Market Sizes by Technology

  • 10.1 Sanger Sequencing Market
    • 10.1.1 Table - Sanger by Country
    • 10.1.2 Chart - Sanger Segment Growth
  • 10.2 NGS/2G Market
    • 10.2.1 Table NGS/2G by Country
    • 10.2.2 Chart - NGS/2G Growth
  • 10.3 3G/Long Market
    • 10.3.1 Table - 3G/Long by Country
    • 10.3.2 Chart - 3G/Long Growth
  • 10.4 Other Technology Market
    • 10.4.1 Table - Other Technology by Country
    • 10.4.2 Chart - Other Technology Growth

11 Market Sizes by Workflow

  • 11.1 Sequencing Market
    • 11.1.1 Table - Sequencing by Country
    • 11.1.2 Chart - Sequencing Segment Growth
  • 11.2 Sample Prep Market
    • 11.2.1 Table Sample Prep by Country
    • 11.2.2 Chart - Sample Prep Growth
  • 11.3 Analysis Market
    • 11.3.1 Table - Analysis by Country
    • 11.3.2 Chart - Analysis Growth

12 Market Sizes by Product

  • 12.1 Instruments Market
    • 12.1.1 Table - Instruments by Country
    • 12.1.2 Chart - Instruments Segment Growth
  • 12.2 Consumables Market
    • 12.2.1 Table Consumables by Country
    • 12.2.2 Chart - Consumables Growth
  • 12.3 Software & Services Market
    • 12.3.1 Table - Software & Services by Country
    • 12.3.2 Chart - Software & Services Growth

13 Vision of the Future of Human Gene Sequencing

14 Appendices

  • 14.1 United States Medicare System: January 2021 laboratory Fees Schedule
  • 14.2 The Whole Genome Sequence of SARS-CoV-2
  • 14.3 Methodology
    • 14.3.1 Authors
    • 14.3.2 Sources

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • Table 3 Lab Spending 2014 to 2024
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Human Gene Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 The Factors Driving Growth
  • Table 9 Factors Limiting Growth
  • Table 10 - Listing of Current NGS Instrument Specifications
  • Table 11 Six New Sequencing Technologies
  • Table 12 - Global Market by Region
  • Table 13 Global Market by Application
  • Table 14 Global Market by Technology
  • Table 15 Global Market by Workflow
  • Table 16 Global Market by Product
  • Table 17 Hereditary Segment by Country
  • Table 18 NIPT Segment by Country
  • Table 19 Oncology Segment by Country
  • Table 20 Psychology Segment by Country
  • Table 21 WGES Segment by Country
  • Table 22 Pharmacogenomics Segment by Country
  • Table 23 DTC Segment by Country
  • Table 24 Research Segment by Country
  • Table 25 Other Application Segment by Country
  • Table 26 Sanger Segment by Country
  • Table 27 NGS/2G Segment by Country
  • Table 28 3G/Long Segment by Country
  • Table 29 Other Technology by Country
  • Table 30 Sequencing Segment by Country
  • Table 31 Sample Prep Segment by Country
  • Table 32 Analysis Segment by Country
  • Table 33 Instruments Segment by Country
  • Table 34 Consumables Segment by Country
  • Table 35 Software & Services Segment by Country
  • Table 36 2021Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Clinical Lab Spending 2014 to 2024
  • Figure 2 Gene Sequencing
  • Figure 3 Global Illumina Installed Base Map
  • Figure 4 TruSight Germline Panel
  • Figure 5 Historical Cost of Gene Sequencing
  • Figure 6 - Cost To Sequence a Human Genome
  • Figure 7 Base Year Country Market Share Chart
  • Figure 8 Global Market by Application - Base vs. Final Year
  • Figure 9 Global Market by Application Base Year
  • Figure 10 Global Market by Application Final Year
  • Figure 11 Application Type Share by Year
  • Figure 12 by Application Segment Growth
  • Figure 13 Global Market by Technology - Base vs. Final Year
  • Figure 14 Global Market by Technology Base Year
  • Figure 15 Global Market by Technology Final Year
  • Figure 16 Technology Type Share by Year
  • Figure 17 by Technology Segment Growth
  • Figure 18 Global Market by Workflow - Base vs. Final Year
  • Figure 19 Global Market by Workflow Base Year
  • Figure 20 Global Market by Workflow Final Year
  • Figure 21 Workflow Type Share by Year
  • Figure 22 by Workflow Segment Growth
  • Figure 23 Global Market by Product - Base vs. Final Year
  • Figure 24 Global Market by Product Base Year
  • Figure 25 Global Market by Product Final Year
  • Figure 26 Product Type Share by Year
  • Figure 27 by Product Segment Growth
  • Figure 28 Hereditary vs. Total Market Growth
  • Figure 29 NIPT vs. Total Market Growth
  • Figure 30 Oncology vs. Total Market Growth
  • Figure 31 Psychology vs. Total Market Growth
  • Figure 32 WGES vs. Total Market Growth
  • Figure 33 Pharmacogenomics vs. Total Market Growth
  • Figure 34 DTC vs. Total Market Growth
  • Figure 35 Research vs. Total Market Growth
  • Figure 36 Other Application vs. Total Market Growth
  • Figure 37 Sanger vs. Total Market Growth
  • Figure 38 NGS/2G vs. Total Market Growth
  • Figure 39 3G/Long vs. Total Market Growth
  • Figure 40 Other Technology vs. Total Market Growth
  • Figure 41 Sequencing vs. Total Market Growth
  • Figure 42 Sample Prep vs. Total Market Growth
  • Figure 43 Analysis vs. Total Market Growth
  • Figure 44 Instruments vs. Total Market Growth
  • Figure 45 Consumables vs. Total Market Growth
  • Figure 46 Software & Services vs. Total Market Growth